Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's leadership, including CEO David-Alexandre C. Gros, M.D., and Chief Scientific Officer and President Steve Perrin, Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT).
Interested parties can register in advance for the presentation webcast through a provided link. Following the live session, a replay of the webcast will be made available on the Company's website in the Events section.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha annunciato la sua partecipazione alla prossima Guggenheim Securities SMID Cap Biotech Conference. La leadership dell'azienda, tra cui il CEO David-Alexandre C. Gros, M.D., e il Chief Scientific Officer e Presidente Steve Perrin, Ph.D., parteciperanno a una chiacchierata informale programmata per mercoledì 5 febbraio 2025, alle 13:00 ET (10:00 PT).
Le parti interessate possono registrarsi in anticipo per il webcast della presentazione tramite un link fornito. Dopo la sessione dal vivo, una registrazione del webcast sarà resa disponibile sul sito web dell'azienda nella sezione Eventi.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha anunciado su participación en la próxima Guggenheim Securities SMID Cap Biotech Conference. El liderazgo de la compañía, incluido el CEO David-Alexandre C. Gros, M.D., y el Director Científico y Presidente Steve Perrin, Ph.D., participará en una charla programada para miércoles 5 de febrero de 2025, a la 1:00 p.m. ET (10:00 a.m. PT).
Las partes interesadas pueden registrarse por adelantado para el webcast de la presentación a través de un enlace proporcionado. Después de la sesión en vivo, se pondrá a disposición una repetición del webcast en el sitio web de la compañía en la sección Eventos.
엘레돈 제약(Eledon Pharmaceuticals) (Nasdaq: ELDN)는 다가오는 구겐하임 증권 SMID 캡 생명공학 회의에 참여한다고 발표했습니다. 회사의 리더십, CEO인 David-Alexandre C. Gros, M.D.와 수석 과학 책임자 및 사장인 Steve Perrin, Ph.D.가 2025년 2월 5일 수요일 오후 1:00 ET (오전 10:00 PT)에 예정된 대화에 참여할 것입니다.
관심 있는 분들은 제공된 링크를 통해 발표 웹캐스트에 미리 등록할 수 있습니다. 라이브 세션 후, 웹캐스트의 재생이 회사 웹사이트의 이벤트 섹션에 공개됩니다.
Eledon Pharmaceuticals (Nasdaq: ELDN) a annoncé sa participation à la prochaine Guggenheim Securities SMID Cap Biotech Conference. La direction de l'entreprise, y compris le PDG David-Alexandre C. Gros, M.D., et le Responsable scientifique et Président Steve Perrin, Ph.D., participera à une discussion informelle prévue pour mercredi 5 février 2025 à 13h00 ET (10h00 PT).
Les parties intéressées peuvent s'inscrire à l'avance pour le webinaire de présentation via un lien fourni. Après la session en direct, un enregistrement du webinaire sera disponible sur le site web de l'entreprise dans la section Événements.
Eledon Pharmaceuticals (Nasdaq: ELDN) hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference angekündigt. Die Unternehmensführung, einschließlich CEO David-Alexandre C. Gros, M.D., und Chief Scientific Officer und Präsident Steve Perrin, Ph.D., wird an einem geplanten Gespräch teilnehmen, das für Mittwoch, den 5. Februar 2025, um 13:00 Uhr ET (10:00 Uhr PT) angesetzt ist.
Interessierte Parteien können sich im Voraus über einen bereitgestellten Link für das Präsentations-Webcast registrieren. Nach der Livesitzung wird eine Wiederholung des Webcasts auf der Website des Unternehmens im Bereich Veranstaltungen verfügbar sein.
- None.
- None.
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT).
To register in advance for the presentation webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When is Eledon Pharmaceuticals (ELDN) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
Who will represent ELDN at the Guggenheim Biotech Conference 2025?
How can investors access ELDN's Guggenheim Conference presentation?
What type of presentation will ELDN deliver at the Guggenheim SMID Cap Conference?
